| Assessment Status | Rapid Review complete |
| HTA ID | 22033 |
| Drug | Cholecalciferol |
| Brand | Egostar® |
| Indication | Prevention of vitamin D deficiency in adult patients with an identified risk, initial treatment of clinically relevant vitamin D deficiency, and as an adjunct to specific therapy for osteoporosis in patients with vitamin D deficiency or at risk of vitamin D insufficiency. |
| Assessment Process | |
| Rapid review commissioned | 11/05/2022 |
| Rapid review completed | 23/06/2022 |
| Rapid review outcome | A full HTA is not recommended. The NCPE recommends that Egostar® not be considered for reimbursement at the submitted price*. |
*This recommendation should be considered while also having regard to the criteria specified in the Health (Pricing and Supply of Medical Goods) Act 2013.
The HSE has approved reimbursement, March 2023.
